Tricyclic benzazepine and benzothiazepine derivatives
申请人:Meiji Seika Kabushiki Kaisha
公开号:US05686442A1
公开(公告)日:1997-11-11
The tricyclic benzazepine and benzothiazepine derivatives represented by the formula (I) and pharmacologically acceptable salts thereof are disclosed. ##STR1## wherein Z represents CO, --CR.sup.6 R.sup.7 -- or --S(O).sub.n, R represents hydrogen, alkyl, phenylalkyl, or a protective group of a triazole ring, R.sup.1 -R.sup.5 represent hydrogen, alkyl, alkenyl, alkoxy, amino, oxim or hydroxyl. These compounds have anti-allergic effect and are useful for the treatment and prophylaxis of allergic diseases.
PRODUCTION PROCESS FOR FLUOROSULFONYLIMIDE AMMONIUM SALT
申请人:Tsubokura Shiro
公开号:US20130331609A1
公开(公告)日:2013-12-12
A compound [II] such as ammonium N,N-di(fluorosulfonyl)imide is obtained by reacting a compound [I] such as N,N-di(chlorosulfonyl)imide and NH
4
F (HF)
p
. A compound [IV] such as an N,N-di(fluorosulfonyl)imide alkali metal salt is obtained by reacting the obtained compound [II] and an alkali metal compound or the like.
A process for producing an arylamine is provided which is characterized by reacting an aromatic halogen compound with an aromatic amine in the presence of an organic salt selected from specific pyridinium salts, imidazolium salts and quaternary onium salts, a copper catalyst, and a base. Thus, the reaction of even an aromatic halogen compound substituted by an electron-donating group proceeds efficiently, and an inexpensive chlorinated aromatic compound or brominated aromatic compound is usable, and an arylamine, in particular a triarylamine or diarylamine, having a high purity can be produced at low cost.
An improved process for producing an ester from a carboxylic acid and an alcohol which comprises reacting said carboxylic acid with said alcohol by the use of a 1-substituted-2-halopyridinium salt or a 1-substituted-2-haloquinolinium salt as a condensing agent in the presence of a hydrogen halide captor. According to this process, various esters, even if they have some steric hindrances, may be obtained in good yields.
Tetrahydroisoquinoline Compound and Medicinal Use Thereof
申请人:Takahashi Kenji
公开号:US20100022582A1
公开(公告)日:2010-01-28
The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.